PI3K Inhibition in Combination with Tamoxifen in Patients with Metastatic HR+/HER2- Breast Cancer: Clinical and Circulating Tumor DNA Results.

Saved in:
Bibliographic Details
Title: PI3K Inhibition in Combination with Tamoxifen in Patients with Metastatic HR+/HER2- Breast Cancer: Clinical and Circulating Tumor DNA Results.
Authors: Voorthuis RAB; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Oliveira M; Department of Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, Spain., van Rossum AGJ; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., de Boo LW; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Mandjes IAM; Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Saura C; Department of Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, Spain., Muñoz S; Department of Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, Spain., López García D; Department of Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, Spain., Schrier M; Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Sikorska K; Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Lopez-Yurda M; Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Schot M; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Westphal T; Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Korse CM; Clinical Laboratory of the Netherlands Cancer Institute, Amsterdam, the Netherlands., Anand S; Cancer Molecular Diagnostics Laboratory, CRUK Cambridge Cancer Centre, Cambridge, United Kingdom., Bernards R; Divisions of Diagnostic Oncology, Radiotherapy and Molecular Carcinogenesis and Center for Biomedical Genetics, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Gallaher WM; UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, St. Vincent's-UCD Cancer Centre, University College Dublin, Dublin, Ireland., Beelen K; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Caldas C; Cancer Research UK Cambridge Centre , Cambridge, United Kingdom., Cortes J; Department of Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, Spain.; Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid, Spain., Linn SC; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands., Baird RD; Cancer Research UK Cambridge Centre , Cambridge, United Kingdom.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2026 May 15; Vol. 32 (10), pp. 1983-1994.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1557-3265
DOI:10.1158/1078-0432.CCR-25-2833